MSU
TCRX icon

Mizuho Securities USA’s TScan Therapeutics TCRX Stock Holding History

Mizuho Securities USA’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$10.1K – 697
2025
Q4 		$10.1K Buy
+10,000
New +$14.5K ﹤0.01% 689

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Mizuho Securities USA's TCRX Position: Q1 2026 in Review

Mizuho Securities USA sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 10,000 shares — an estimated $10.1K sold.

Mizuho Securities USA first reported a position in TCRX in Q4 2025 and held it in 1 quarter. The position peaked at $10.1K in Q4 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Mizuho Securities USA reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mizuho Securities USA sold 10,000 TScan Therapeutics shares in Q1 2026, an estimated $10.1K.
  • Mizuho Securities USA first reported a position in TScan Therapeutics in Q4 2025 and held it in 1 quarter.
  • Mizuho Securities USA's TScan Therapeutics position peaked at $10.1K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Mizuho Securities USA's 13F filing for Q1 2026, filed 11 May 2026.